SideROS was selected for the 2020 EIT Health Headstart program providing emerging companies with mentorship and funding opportunities for their innovative products and services aiming to improve the lives of European patients and citizens.
Ninety-six start-ups from across Europe have been selected to take part in the annual EIT Health Headstart programme. The start-ups picked up are granted mentoring and business support, and financial support of up to €50,000, and will make valuable contacts within the health innovation ecosystem via EIT Health’s vast network.
Sideors bridges innovation via research on iron-targeting chemical compounds and drug candidate discoveries to target persister cancer cells. Their innovative approach uses small molecules that show the potential to target various types of cancer, thereby revolutionising treatment.